Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed ...

Novo Nordisk ended the phase three trial in October, a year earlier than expected, in response to positive results. At the ...

Novo Nordisk’s cannabinoid CB1 receptor blocker ... the Danish drugmaker has reported the failure of a midphase diabetic kidney disease trial of the molecule. CB1 receptor blockade is an old ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Parvus Asset Management is building a stake in Novo Nordisk and hopes to influence its choice of a new CEO. Novo Nordisk ...

Semaglutide has already shown its value in reducing complications of being overweight, such as cardiovascular issues and kidney disease, and Novo Nordisk ... in the STEP 9 trial.

March is National Kidney ... clinical trial which led to this approval, joins us to share some insight into the news and what it means for patients. Richard Pratley, MD is a paid Novo Nordisk ...

Novo Nordisk today presented the full ... and/or chronic kidney disease (CKD). These new data from the phase 3b trial were featured during a late-breaking clinical trial session at the American ...